Status:

UNKNOWN

Effect of 6R-BH4 Treatment in Coronary Artery Disease (OXBIO Study)

Lead Sponsor:

University of Oxford

Collaborating Sponsors:

BioMarin Pharmaceutical

Conditions:

Coronary Artery Disease

Eligibility:

All Genders

18+ years

Phase:

PHASE2

Brief Summary

The purpose of this study is to determine the effect of 6R-BH4 on vascular function in patients with coronary artery disease. We hypothesize that 6R-BH4 will improve vascular function in these patient...

Detailed Description

Decreased production of nitric oxide (NO) from the endothelium (the layer of cells that forms the lining of all blood vessels) has been shown to contribute to atherosclerosis. NO has multiple benefici...

Eligibility Criteria

Inclusion

  • Multi-vessel coronary artery disease scheduled for coronary artery bypass surgery (CABG)

Exclusion

  • Inability to provide informed consent
  • Female subject who is pregnant, lactating or planning pregnancy during course of study
  • Prior clinical diagnosis of heart failure requiring diuretic therapy with evidence of severe left ventricular dysfunction
  • Recent acute coronary event (\<4 weeks)
  • Emergency CABG
  • Newly diagnosed diabetes mellitus (\<1 month)
  • Body weight \>130kg
  • Impaired renal function (creatinine \>180umol/l)
  • Elevated liver function tests (ALT \>50umol/l or AST \>2x normal)
  • Pacemakers, ICDs or metallic implants not compatible with MRI scanning
  • Subjects receiving experimental medications or participating in another study
  • Terminally ill subjects
  • Known hypersensitivity to 6R-BH4
  • Concomitant treatment with methotrexate, levodopa, PDE-3 or PDE-5 inhibitors

Key Trial Info

Start Date :

November 1 2006

Trial Type :

INTERVENTIONAL

Allocation :

ESTIMATED

End Date :

February 1 2009

Estimated Enrollment :

66 Patients enrolled

Trial Details

Trial ID

NCT00423280

Start Date

November 1 2006

End Date

February 1 2009

Last Update

August 7 2008

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

Department of Cardiovascular Medicine, University of Oxford

Oxford, United Kingdom, OX3 9DU